


# Peptides plus antibiotic combination may result in a more effective treatment for leishmaniasis

16 October 2020



Schematic representation of how the conjugate of the peptide + the drug manages to enter inside the cell of the parasite to eliminate it (UAB). Credit: UAB

Leishmaniasis is caused by the protozoan *Leishmania* parasites which are transmitted by the bite of an infected sandfly. Although in rich countries this disease mainly affects dogs, in other countries it can wreak havoc on the health of humans, causing anything from ulcers to damage to the bone marrow, liver or spleen, all which could be fatal. The WHO estimates that there are currently over one billion people living in areas in which leishmaniasis is endemic and that there are over one million new cases each year. There is therefore an urgent need to find new, efficient and selective alternatives to leishmaniasis chemotherapy which can reduce the adverse side effects of existing drugs such as paromomycin and miltefosine.

Lecturers Rosa Maria Ortuño and Ona Illa from the UAB Department of Chemistry were in charge of coordinating a multidisciplinary research into finding new anti-*Leishmania* therapies. Also involved in the study were the groups of lecturer

Jean-Didier Maréchal, from the same department, and of lecturer Carme Nogués, from the UAB Department of Cell Biology, Physiology and Immunology, as well as researchers Luis Rivas from the CIB Margarita Salas—CSIC (Madrid) and Míriam Royo from the IQAC—CSIC (Barcelona).

The study consisted in the preparation and biological evaluation of new cell-penetrating peptides (CPPs) which, with an antibiotic conjugation, serve as a vehicle or vector for the [drug](#), enabling it to enter the parasite's cell membrane and be released inside, thus causing its death. The result is greater effectiveness, while at the same time a lower number of oral doses of the drug are needed. In addition, the synthesized CPPs are not toxic for mammal cells, but are for the *Leishmania*. "Although the idea of using CPPs in the treatment of leishmaniasis is not unknown, the importance of this study lies in its high cell-penetrating capacity and the selectivity (mammal vs parasite cells) of the new synthesized and studied peptides," explains Rosa Maria Ortuño.

In particular, the research has served to study peptides made up of non-protein [amino acids](#) with a covalent conjugate of doxorubicin (dox), a drug which is also used in cancer treatments. While dox in its free form is not active when incubated with *Leishmania* because it is not capable of penetrating its interior, the dox-PPC conjugate has demonstrated to be toxic in very low concentrations. Its cell-penetrating capacity has been rationalized through molecular modeling studies. The results are highly promising, and "a great deal of research is still needed before thinking about new drugs, but we are now a little bit closer of our objective," concludes Ortuño.

**More information:** Ona Illa et al, Chiral Cyclobutane-Containing Cell-Penetrating Peptides

as Selective Vectors for Anti-Leishmania Drug  
Delivery Systems, *International Journal of  
Molecular Sciences* (2020). DOI:  
[10.3390/ijms21207502](https://doi.org/10.3390/ijms21207502)

Provided by Autonomous University of Barcelona  
APA citation: Peptides plus antibiotic combination may result in a more effective treatment for  
leishmaniasis (2020, October 16) retrieved 12 October 2022 from  
<https://medicalxpress.com/news/2020-10-peptides-antibiotic-combination-result-effective.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*